Tuesday, August 3, 2021 - Sanofi, the maker of Zantac, has rebranded their flagship medicine in the wake of thousands of lawsuits accusing them of covering up their knowledge about ranitidine becoming carcinogenic over time or if exposed to high temperatures. The company is under criminal investigation by the US Department of Justice (DOJ) and accused by plaintiff attorneys of deleting critical emails that prove the former. It is misleading to celebrate the return of Zantac after being recalled on April 1, 2020, due to concerns the heartburn medicine caused cancer. Believing that the original Zantac has returned is untrue because the Zantac on the market today is entirely different from the one that allegedly causes stomach, bladder, esophagus, prostate, colon, and other cancer. The Zantac that was subject to recall was ranitidine. The Zantac 360 now on the market is famotidine. Both are types of medicine used to alleviate heartburn, acid indigestion, and gastrointestinal reflux disease pain. Famotidine takes longer to start to work, is stronger, and lasts longer than ranitidine. The National Institute of Health reports on the alarmingly stronger famotidine. "Famotidine, an H2-receptor antagonist with a thiazole nucleus, is approximately 7.5 times more potent than ranitidine." Zantac 360 famotidine is the same as Pepcid AC famotidine. According to the Pepcid AC website, "Famotidine is a histamine-2 blocker. It works by decreasing the amount of acid the stomach produces by blocking the histamine receptors in your stomach responsible for triggering acid production." Both ranitidine and famotidine have a list of common side effects of which users should be aware. Drugs.com warns famotidine users to expect the following: confusion, hallucinations, agitation, lack of energy; a seizure; fast or pounding heartbeats, sudden dizziness (like you might pass out); or, unexplained muscle pain, tenderness, or weakness especially if you also have a fever, unusual tiredness, and dark colored urine."
Thousands of former Zantac users have registered with Zantac Cancer attorneys to file lawsuits alleging the use of the heartburn medicine regularly for more than a year caused them to develop one form or another of life-threatening cancer. Zantac ranitidine has been tested to contain levels of carcinogenic N-nitrosodimethylamine (NDMA) higher than what the Food and Drug Administration (FDA) deems to be acceptable in a medicine that is to be taken several times a day in perpetuity. There is much controversy surrounding the testing method used by online prescription drug testing pharmacy Valisure. Valisure scientists are being criticized for using gas Chromatography testing which heats the sample being tested. Zantac lawsuits are consolidated into multidistrict litigation (MDL) so that the universal and complex science underlying the plaintiff‘s claims about ranitidine can be decided upon. A science day will be held next month and the judge will interview dozens of expert witnesses from both sides and then decide on which ones will be allowed to go before the juries. If all goes as planned, the first bellwether trial will start in 2023, pandemic delays aside.